Contributors

ATLANTA—Womble Carlyle was a sponsor of the 2016 Women in Law Reception, hosted by the Atlanta Women’s Foundation. Attorneys Lisa Bondurant, Jennifer Collins, Chip Presten and Chittam Thakore represented the firm at the event.

The 2016 Women in Law Reception took place June 14th at the Piedmont Driving Club in Atlanta. Former Atlanta Mayor Shirley Franklin was the featured speaker.

Lisa Bondurant is a partner in Womble Carlyle’s Business Litigation Practice Group in the firm’s Atlanta office. Her practice is concentrated in life insurance and financial services litigation, including ERISA.  For more than twenty years, Lisa has been lead counsel on a variety of cases involving complex insurance issues, ERISA, RICO, life, health, disability, and accidental death benefits, broker, producer and agent disputes and managed care litigation.

Jennifer Collins is a member of Womble Carlyle’s Financial Services Litigation Team and regularly represents banks and servicers in class actions, consumer financial litigation, mortgage origination and servicing violations, real estate transaction disputes, and lender liability claims.

Chip Presten represents corporate clients in various aspects of corporate, mergers and acquisitions, and securities practice, including private equity transactions, acquisition and divestiture of public and private companies, and offerings of debt and equity securities. Presten also represents private equity funds and their investors in connection with fund formation issues, securities law issues and portfolio company transactions, and he has advised companies being acquired by or seeking capital from such funds. 

Chittam Thakore is an Intellectual Property attorney with a particular background in pharmaceutical patents. Her practice includes counseling clients in ANDA and Hatch-Waxman Act litigation. Chittam is a Ph.D. biologist whose research experience includes bidirectional interactions between PKC-epsilon and beta-1 integrins in human prostate cancer cells. She also has written on IP issues surrounding generic drugs.